COMP <GO>
ORMP vs SION // EV/EBITDA & P/E VALUATION
Oramed Pharmaceuticals Inc. (NASDAQ) VS. Sionna Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ORMP 3
— SION 1
■ METRIC PARITY
LAST: $4.11 (-2.84%) • MKT CAP: $176.0M
valuation
—
LAST: $3.87 (-3.25%) • MKT CAP: $180.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORMP VS. SION)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORMP | SION | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -7.80% | -28.30% | +20.50 | ORMP | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.20% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 3.80% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ORMP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.0 | 29.4 | +7.52 | ORMP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $176.0M | $180.8M | -$4.9M | SION | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORMP REV | SION REV | ORMP GROSS % | SION GROSS % | ORMP FCF | SION FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | $0 | 0.7% | — | -$9.2M | -$66.7M |
| FY 2024 | $0 | $0 | — | — | -$8.4M | -$52.8M |
| FY 2023 | $1.3M | — | — | — | -$10.3M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORMP // BETA —
SION // BETA —